‘Big data’ is delivering on its promise to improve drug development, with machine learning and artificial intelligence (AI) decoding disease much cheaper than previous technologies, and high-throughput workflows decoding network biology much faster. Ochre Bio’s approach is firmly rooted in such computational and systems-driven learning. However, the company’s goal is also to decode substantially better, by deep phenotyping of human organs.
Deep phenotyping combines genetics, advanced tissue imaging, cellular genomics (single-cell and spatial sequencing) and machine learning to study disease and gene systems at the tissue level. As population genetics grows in importance as a tool to de-risk targets, deep phenotyping is following suit to fill in the important functional details. At Ochre Bio, this means the deep phenotyping of human biobanks, high throughput human micro-organ (in vitro) models, and entire human organs maintained in organ transplant perfusion devices.
Lexogen provides RNA-Seq services at the expert level, covering the whole workflow from consultation to RNA extraction, library preparation, next-generation sequencing and data analysis. As the inventors of world-class technologies, Lexogen provides highest quality analyses for standard gene expression experiments, as well as for challenging samples and applications. They routinely handle a wide range of RNA input, from standard quality to FFPE-extracted and degraded RNA, stemming from sources like tissues, cell culture, biofluids and single cells. This is matched by standardized and advanced data analyses, as well as the option for automation to handle large-scale projects.
Register for this webinar to hear Dr. Quin Wills provide a brief overview of functional genomic trends in drug discovery, followed by a recently completed project to spatially sequence 1000 human livers over the early NAFLD spectrum. He’ll end with how he believes this can transform the study of age-related chronic diseases that have long silent clinical trajectories before presenting with complications.
Quin Wills, Co-founder and CSO, Ochre Bio
Quin is an MD, with further degrees in genetics, mathematics and computational biology and a doctorate in systems genomics. He founded his first liver drug genomics company 15 years ago, has steered research consortia that use genomics tools such as single-cell sequencing and most recently founded the advanced genomics department for a leading pharma before returning to the world of biotech with Ochre Bio.Message Presenter
Lukas Paul, Product Manager, Lexogen
Lukas Paul worked at Lexogen in several roles, co-developing kits, services and scientific affairs before becoming a product manager. He holds a PhD in Biomolecular Sciences from the University of Manchester, completed a PostDoc at the University of Vienna, and contributed as Staff Scientist at the Max F. Perutz Laboratories. His academic work includes studies on RNA-protein interaction, enzymatics, RNA degradation, translation, ribosome recycling, catalytic RNA and fluorescence assay development. In his current position at Lexogen, Lukas Paul manages the product portfolio part that includes services, external controls, metabolic labeling, data analysis and custom design.Message Presenter
Who Should Attend?
- Academic/Research Labs
- Biotech/Pharma Company
- NGS Core Facility
- Principal Investigator/Professor/Scientist/
- Personnel Working in Expression Profiling or Target-Specific RNA-Sequencing
What You Will Learn
- Translational trends in deep phenotyping genomics
- The applications of spatial sequencing and imaging AI to dissect pathological changes in the liver with age and obesity
- How difficult samples (including FFPE-derived RNA) can be analyzed
- How spike-in controls can contribute to RNA-Seq quality control
Lexogen is a next generation sequencing and transcriptomics company. As the RNA experts we focus on empowering scientists with innovative top quality RNA analysis solutions and support, in order to improve health and well-being for everyone on the planet.
The product portfolio of Lexogen includes innovative kits for single-cell as well as bulk RNA-Seq, RNA purification and ribosomal RNA depletion, spike-in RNA variant controls, and metabolic RNA labeling.
Lexogen also provides top-class fully integrated RNA-Seq service-workflows including sample preparation, multiplexed sequencing, data analysis, and report generation.
The company headquarters is based in Vienna, Austria and the North American office is in Greenland, New Hampshire, USA. Lexogen is represented by multiple distributors around the world.
To learn more, visit www.lexogen.com and follow @lexogen on Twitter and LinkedIn.